SUCCESSFUL TREATMENT FREE REMISSION IN CML AFTER 2 YEAR CONSOLIDATION WITH NILOTINIB OF AN MR4.5 RESPONSE LEVEL ACHIEVED ORIGINALLY WITH IMATINIB TREATMENT: FIRST REPORT FROM STAT2 TRIAL IN JAPAN
HAEMATOLOGICA(2016)
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined